There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

The unusual move at FDA comes shortly after the agency's longtime vaccine chief was forced out over disagreements with Makary ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax WASHINGTON -- The Trump administration's effort to impose new ...

Novavax's recent performance shows improvement, but significant challenges persist, impacting long-term growth and stability. The company's financials have strengthened due to strategic moves ...

WASHINGTON — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is ...